Indaptus Therapeutics, Inc. (NASDAQ:INDP) Sees Large Growth in Short Interest

Indaptus Therapeutics, Inc. (NASDAQ:INDP) saw a large growth in short interest in the month of October. As of October 31st, there was short interest totalling 138,700 shares, a growth of 348.9% from the October 15th total of 30,900 shares. Based on an average daily volume of 108,000 shares, the short-interest ratio is currently 1.3 days. Approximately 1.9% of the company’s stock are short sold.

Hedge Funds Weigh In On Indaptus Therapeutics

An institutional investor recently bought a new position in Indaptus Therapeutics stock. Virtu Financial LLC bought a new stake in Indaptus Therapeutics, Inc. (NASDAQ:INDP) during the first quarter, according to its most recent filing with the SEC. The firm bought 14,232 shares of the company’s stock, valued at approximately $32,000. Virtu Financial LLC owned about 0.17% of Indaptus Therapeutics at the end of the most recent quarter. 7.06% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Separately, HC Wainwright restated a “buy” rating and set a $12.00 price target on shares of Indaptus Therapeutics in a report on Wednesday, October 16th.

Indaptus Therapeutics Trading Down 5.0 %

NASDAQ INDP traded down $0.06 during trading on Tuesday, hitting $1.15. 9,330 shares of the company traded hands, compared to its average volume of 64,114. Indaptus Therapeutics has a 12 month low of $1.03 and a 12 month high of $3.10. The business has a fifty day simple moving average of $1.34 and a 200 day simple moving average of $1.85. The company has a market capitalization of $11.73 million, a P/E ratio of -0.65 and a beta of 1.45.

Indaptus Therapeutics (NASDAQ:INDP) last posted its earnings results on Monday, August 12th. The company reported ($0.47) earnings per share for the quarter, topping the consensus estimate of ($0.54) by $0.07. Equities research analysts predict that Indaptus Therapeutics will post -1.79 EPS for the current fiscal year.

Indaptus Therapeutics Company Profile

Indaptus Therapeutics, Inc, a clinical biotechnology company, develops various anti-cancer and anti-viral immunotherapy products. Its lead clinical candidate is Decoy20 used to produce single agent activity and/or combination therapy-based durable responses of lymphoma, hepatocellular, colorectal, and pancreatic tumors, and chronic hepatitis B virus, and human immunodeficiency virus infection, which is in Phase 2 clinical trial.